United Therapeutics Stock Investor Sentiment

UTHR Stock  USD 370.12  0.37  0.1%   
Slightly above 61% of United Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding United Therapeutics suggests that many traders are alarmed. United Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in United Therapeutics. Many technical investors use United Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
over three months ago at www.macroaxis.com         
Disposition of 1305 shares by Rothblatt Martine A of United Therapeutics at 274.7229 subject to Rule...
Macroaxis News
over three months ago at news.google.com         
KBC Group NV Increases Stock Holdings in United Therapeutics Co. - MarketBeat
Google News at Macroaxis
over three months ago at investing.com         
Disposition of 1067 shares by Rothblatt Martine A of United Therapeutics at 277.3808 subject to Rule...
Investing News at Macroaxis
over three months ago at zacks.com         
Why United Therapeutics is a Top Value Stock for the Long-Term
zacks News
over three months ago at finance.yahoo.com         
Why United Therapeutics is a Top Value Stock for the Long-Term
Yahoo News
over three months ago at finance.yahoo.com         
Disposition of 164 shares by Rothblatt Martine A of United Therapeutics at 279.3604 subject to Rule ...
Yahoo News
over three months ago at zacks.com         
Ionis Pharmaceuticals Down 0.7 percent Since Last Earnings Report Can It Rebound?
zacks News
over six months ago at investing.com         
Disposition of 1497 shares by Rothblatt Martine A of United Therapeutics at 278.0094 subject to Rule...
Investing News at Macroaxis
over six months ago at businesswire.com         
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Confer...
businesswire News
over six months ago at investing.com         
United Therapeutics CEO Martine Rothblatt sells over 1.9M in company stock
Investing News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 122 shares by Rothblatt Martine A of United Therapeutics at 278.066 subject to Rule 1...
Macroaxis News
over six months ago at investors.com         
Disposition of 266 shares by Rothblatt Martine A of United Therapeutics at 279.4557 subject to Rule ...
Investors Business Daily at Macroaxis
over six months ago at investors.com         
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
Investors Business Daily at Macroaxis
over six months ago at seekingalpha.com         
Disposition of 209 shares by Rothblatt Martine A of United Therapeutics at 274.8588 subject to Rule ...
seekingalpha News
over six months ago at zacks.com         
Why Is United Therapeutics Up 4.8 percent Since Last Earnings Report?
zacks News
Far too much social signal, news, headlines, and media speculation about United Therapeutics that are available to investors today. That information is available publicly through United media outlets and privately through word of mouth or via United internal channels. However, regardless of the origin, that massive amount of United data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of United Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of United Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to United Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive United Therapeutics alpha.

United Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.